Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback Home
Home   COVID-19 treatment studies for Famotidine  COVID-19 treatment studies for Famotidine  C19 studies: Famotidine  Famotidine   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality 11% Improvement Relative Risk Ventilation 12% ICU admission 10% Hospitalization time 17% Recovery time 10% c19early.com/fm Pahwani et al. Famotidine for COVID-19 RCT LATE TREATMENT Favors famotidine Favors control
Pahwani, 178 patient famotidine late treatment RCT: 11% lower mortality [p=1], 12% lower ventilation [p=0.73], 10% lower ICU admission [p=0.86], and 17% shorter hospitalization [p<0.0001] https://c19p.org/pahwani
copied to clipboard
Efficacy of Oral Famotidine in Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2
Pahwani et al., Cureus, doi:10.7759/cureus.22404
20 Feb 2022    Source   PDF   Share   Tweet
RCT with 89 famotidine and 89 control patients in Pakistan, showing faster recovery but no significant difference in mortality. 40mg oral famotidine daily.
risk of death, 11.1% lower, RR 0.89, p = 1.00, treatment 8 of 89 (9.0%), control 9 of 89 (10.1%), NNT 89.
risk of mechanical ventilation, 12.5% lower, RR 0.88, p = 0.73, treatment 21 of 89 (23.6%), control 24 of 89 (27.0%), NNT 30.
risk of ICU admission, 10.0% lower, RR 0.90, p = 0.86, treatment 18 of 89 (20.2%), control 20 of 89 (22.5%), NNT 44.
hospitalization time, 16.5% lower, relative time 0.83, p < 0.001, treatment mean 8.6 (±1.6) n=89, control mean 10.3 (±2.2) n=89.
recovery time, 9.6% lower, relative time 0.90, p = 0.001, treatment mean 8.5 (±1.7) n=89, control mean 9.4 (±1.9) n=89.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Pahwani et al., 2/20/2022, Randomized Controlled Trial, Pakistan, South Asia, peer-reviewed, mean age 52.0, 8 authors, study period December 2020 - September 2021.
All Studies   Meta Analysis
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit